Published in Br J Cancer on September 23, 2014
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell (2016) 0.87
Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA. Haematologica (2016) 0.80
A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells. Oncotarget (2016) 0.75
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Cell Death Dis (2017) 0.75
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell (2005) 9.22
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell (2007) 3.16
PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature (2010) 2.91
A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol Cell (2010) 2.77
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature (2010) 2.20
Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell (2000) 2.02
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat Struct Mol Biol (2010) 1.91
Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood (2011) 1.85
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood (2011) 1.79
PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell (2010) 1.75
Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol (2011) 1.73
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood (2012) 1.61
Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene (2001) 1.59
Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell (2006) 1.53
Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia (2003) 1.49
Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell (2006) 1.48
Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell (2000) 1.47
PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an Nepsilon-dimethyl lysine demethylase. Hum Mol Genet (2009) 1.44
Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell (2007) 1.44
RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell (2007) 1.43
The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell (2013) 1.38
Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell (2011) 1.33
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood (2008) 1.30
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett (2009) 1.29
Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood (2007) 1.28
Curing APL through PML/RARA degradation by As2O3. Trends Mol Med (2011) 1.27
PHF8 targets histone methylation and RNA polymerase II to activate transcription. Mol Cell Biol (2010) 1.25
The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev (2009) 1.24
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood (2013) 1.19
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol (2013) 1.14
Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol (2001) 1.10
Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer (2011) 1.08
Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood (2009) 1.06
Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood (2002) 1.06
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood (2012) 0.99
Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol (2006) 0.99
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol (2008) 0.98
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia (2012) 0.97
SnapShot: Acute myeloid leukemia. Cancer Cell (2012) 0.96
DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev (2011) 0.92
Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett (2011) 0.91
PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res (2010) 0.90
miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene (2012) 0.89
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother (2012) 0.87
Overcoming treatment resistance in acute promyelocytic leukemia and beyond. Oncotarget (2013) 0.86
Characterisation of genome-wide PLZF/RARA target genes. PLoS One (2011) 0.86
The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. Biochim Biophys Acta (2012) 0.82
Histone deacetylase inhibitors in APL and beyond. Curr Top Microbiol Immunol (2007) 0.79
Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: Emerging opportunity and challenge. Cancer Cell (2010) 0.78
Targeting agents alone to cure acute promyelocytic leukemia. N Engl J Med (2013) 0.77